HONG KONG – Clinical-stage biotech Guangzhou Magpie Pharmaceutical Inc. closed a series B financing round and raised nearly ¥100 million (US$14.8 million) to move its first-in-class core asset for the treatment of ischemic stroke and other drug candidates further into the clinic. Sangel Capital is backing the round on its own.